Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Rinner, B; Gandolfi, G; Meditz, K; Frisch, MT; Wagner, K; Ciarrocchi, A; Torricelli, F; Koivuniemi, R; Niklander, J; Liegl-Atzwanger, B; Lohberger, B; Heitzer, E; Ghaffari-Tabrizi-Wizsy, N; Zweytick, D; Zalaudek, I.
MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line.
Sci Rep. 2017; 7(1): 2098-2098. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Frisch Marie-Therese
Ghaffari Tabrizi-Wizsy Nassim
Heitzer Ellen
Liegl-Atzwanger Bernadette
Lohberger Birgit
Meditz Katharina
Rinner Beate
Wagner Karin
Zalaudek Iris
Gendermonitor:
Altmetrics:

Number of Figures: 8
| | | | | | | |
Abstract:
NRAS mutation in melanoma has been associated with aggressive tumor biology and poor prognosis. Although targeted therapy has been tested for NRAS mutated melanoma, response rates still appear much weaker, than in BRAF mutated melanoma. While plenty of cell lines exist, however, only few melanogenic cell lines retain their in vivo characteristics. In this work we present an intensively pigmented and well-characterized cell line derived from a highly aggressive NRAS mutated cutaneous melanoma, named MUG-Mel2. We present the clinical course, unique morphology, angiogenic properties, growth characteristics using in vivo experiments and 3D cell culture, and results of the exome gene sequencing of an intensively pigmented melanogenic cell line MUG-Mel2, derived from a cutaneous metastasis of an aggressive NRAS p. Q61R mutated melanoma. Amongst several genetic alterations, mutations in GRIN2A, CREBP, PIK3C2G, ATM, and ATR were present. These mutations, known to reinforce DNA repair problems in melanoma, might serve as potential treatment targets. The aggressive and fast growing behavior in animal models and the obtained phenotype in 3D culture reveal a perfect model for research in the field of NRAS mutated melanoma.

© Meduni Graz Impressum